Anupam Rasayan India Limited
All news and filings related to Anupam Rasayan India Limited.
View all news & filings- Medium impact
Anupam Rasayan completes ₹60.88 Cr preferential acquisition of Tanfac Industries shares
Anupam Rasayan India Limited has completed the acquisition of 2,60,065 equity shares in Tanfac Industries Limited for ₹60.88 crore via a preferential issue. The shares were acquired at ₹2,341 each. The company executed the acceptance form on September 8, 2026.
Read the summary - Low impact
Anupam Rasayan Announces 23rd AGM on Sep 30, 2026, via VC; E-voting Facility Available
Anupam Rasayan India Limited will hold its 23rd AGM on September 30, 2026, via Video Conference. The Annual Report for FY2025-26 and the AGM notice have been dispatched. Members can cast their votes through e-voting facility. Newspaper advertisements were published on September 09, 2026.
Read the summary - Medium impact
Anupam Rasayan India Ltd. to hold 23rd AGM on Sep 30, 2026; Final dividend of ₹1.5/share proposed
Anupam Rasayan India Limited announced its 23rd AGM on September 30, 2026. A final dividend of ₹1.5 per share for FY26 is proposed. The meeting will adopt FY26 financial statements and consider director re-appointment. Cost auditor remuneration for FY27 is also up for ratification.
Read the summary - Medium impact
Anupam Rasayan Acquires 0.73% Stake in Tanfac Industries for ₹60.88 Crore
Anupam Rasayan India Limited will acquire 2,60,065 equity shares in Tanfac Industries Limited for ₹60.88 crore via preferential issue. The acquisition aims to increase ARIL's stake in Tanfac. The transaction is expected to be completed by September 09, 2026.
Read the summary - Low impact
Anupam Rasayan Appoints Ms. Hetvi Vyas as Deputy CFO & Key Managerial Personnel
Anupam Rasayan India Limited has appointed Ms. Hetvi Vyas as Deputy Chief Financial Officer and Key Managerial Personnel, effective September 08, 2026. Ms. Vyas brings over 9 years of experience in finance and accounting.
Read the summary - Low impact
Anupam Rasayan Fixes Record Date September 18 for Final Dividend FY26
Anupam Rasayan India Limited has set September 18, 2026, as the record date for its final dividend for FY 2025-26. The dividend will be paid on or before October 29, 2026, following its declaration at the 23rd AGM.
Read the summary - High impact
Anupam Rasayan to acquire 2.6 lakh Tanfac shares worth ₹60.88 Cr; approves 23rd AGM.
Anupam Rasayan's Board approved the 23rd AGM on Sept 30, 2026, and set Sept 18 as the record date for dividend. Ms. Hetvi Vyas appointed Deputy CFO. The company will acquire 2.6 lakh shares of Tanfac Industries for ₹60.88 crore via preferential issue.
Read the summary - High impact
Anupam Rasayan inks 6-year chemical supply contract with US-based global industrial major.
Anupam Rasayan has secured a six-year Supply Contract with a US-based global speciality metal manufacturer for a specialty chemical product. Dispatches are expected to begin in the latter half of Q3 FY27. The contract value is variable, based on deliveries.
Read the summary - Low impact
Anupam Rasayan India Ltd. Publishes Post-Offer Advertisement for Bliss GVS Pharma Acquisition
Anupam Rasayan India Limited has published post-offer advertisements for its open offer to acquire 26.00% of Bliss GVS Pharma Limited. The acquisition is being undertaken with Mates Visa Consultancy Private Limited. Advertisements were published on September 1, 2026, in "Financial Express", "Jansatta", and "Nav Shakti".
Read the summary - Medium impact
Anupam Rasayan's Credit Ratings Continued on Watch Developing by Crisil
Anupam Rasayan's credit ratings on ₹1620 Crore bank facilities and ₹160 Crore NCDs remain on Crisil A+/Watch Developing. This follows the acquisition of Bliss GVS Pharma, expected to be funded by debt and equity. The acquisition is anticipated to conclude in September 2026. Revenue rose to ₹2,365 Crore in FY26.
Read the summary - High impact
Anupam Rasayan Q1 FY27 Earnings Call Transcript Released
Anupam Rasayan India Limited (ARIL) reported a 36% YoY growth in consolidated total income to INR 668 crore for Q1 FY27. The company commercialized ETFA using flow chemistry and signed an LOI with BASQUEVOLT for a potential USD 300 million deal over 10 years. The acquisition of Bliss GVS Pharma is expected to complete by early September. Jayhawk contributed 20-22% to revenue with 19-20% EBITDA margins.
Read the summary - Low impact
Anupam Rasayan Submits Newspaper Clippings for Q1 FY27 Unaudited Financial Results
Anupam Rasayan India Limited submitted newspaper clippings for its unaudited financial results for the quarter ended June 30, 2026. Advertisements were published in "Financial Express" and "Dhabkar" on August 15, 2026, with links to full results on the company website.
Read the summary - Low impact
Anupam Rasayan India Q1FY27 Earnings Call Audio Recording Available
Anupam Rasayan India Limited announced that the audio recording of its Q1FY27 earnings call is now available on the company website. The call, held on August 14, 2026, discussed unaudited financial results for the quarter ended June 30, 2026.
Read the summary - High impact
Anupam Rasayan Q1 FY27: Revenue up 36% to ₹667.5 Cr; LOI with BASQUEVOLT for $300M
Anupam Rasayan reported Q1 FY27 consolidated revenue of ₹667.5 Cr, up 36% YoY. EBITDA grew 35% to ₹174.9 Cr. The company commercialized ETFA using flow chemistry and signed an LOI with BASQUEVOLT, S.A. for potential revenue of $300 million over 10 years, expected commercialization in FY27. The acquisition of Bliss GVS Pharma is progressing.
Read the summary - High impact
Anupam Rasayan Q1 FY27 Revenue surges 36% YoY to ₹667.5 Crore; signs $300M deal
Anupam Rasayan reported Q1 FY27 consolidated revenue of ₹667.5 Crore, up 36% YoY. EBITDA increased 35% to ₹174.9 Crore. PAT grew 6% to ₹51.2 Crore. The company signed a Letter of Intent for a potential US$300 million revenue opportunity over ten years and is progressing with the Bliss GVS Pharma acquisition.
Read the summary - Medium impact
Anupam Rasayan Appoints Ravi Desai as Chief Operating Officer
Anupam Rasayan India Limited appointed Mr. Ravi Desai as Chief Operating Officer, effective August 14, 2026. Mr. Desai, previously Sales Head, brings over 20 years of experience in the specialty chemicals industry. The Board of Directors approved the appointment on August 14, 2026.
Read the summary - Medium impact
Anupam Rasayan Q1FY27 Results: Profit Declines 24% to ₹320 Crore, Appoints New COO
Anupam Rasayan reported Q1FY27 standalone net profit of ₹320 crore, down 24% YoY. Consolidated profit was ₹512 crore. Revenue from operations rose to ₹3,288 crore (standalone) and ₹6,549 crore (consolidated). Mr. Ravi Desai was appointed Chief Operating Officer effective August 14, 2026.
Read the summary - Low impact
Anupam Rasayan Schedules Q1FY27 Earnings Call for August 14, 2026
Anupam Rasayan India Limited will hold its Q1FY27 earnings call on August 14, 2026, at 02:00 PM IST to discuss financial results. Key management, including the MD and CFO, will participate.
Read the summary - Medium impact
Anupam Rasayan Publishes Open Offer Ads for Bliss GVS Pharma
Anupam Rasayan India Limited has published advertisements for an open offer to acquire 26% of Bliss GVS Pharma Limited. The ads appeared in "Financial Express," "Jansatta," and "Nav Shakti" on July 27, 2026.
Read the summary - High impact
Anupam Rasayan to acquire 26% stake in Bliss GVS Pharma for ₹829 Crore
Anupam Rasayan India Limited, with Mates Visa Consultancy, is making an open offer to acquire 26% stake in Bliss GVS Pharma for ₹829.03 crore. The offer price is ₹299 per share. The tendering period will be from July 28 to August 10, 2026. An escrow amount of ₹160 crore has been arranged.
Read the summary - Medium impact
Anupam Rasayan publishes newspaper ad for Bliss GVS Pharma open offer
Anupam Rasayan India Limited published a newspaper advertisement on July 18, 2026, concerning an open offer for Bliss GVS Pharma Limited. The offer is to acquire 26.00% of the target company's shares.
Read the summary - Medium impact
Anupam Rasayan completes acquisition of Mates Visa Consultancy, making it a wholly-owned subsidiary.
Anupam Rasayan India Limited acquired 100% of Mates Visa Consultancy Private Limited for ₹10,000 on July 17, 2026. This makes Mates Visa Consultancy a wholly-owned subsidiary. The acquisition is part of a group restructuring and supports the proposed acquisition of Bliss GVS Pharma Limited.
Read the summary - High impact
Anupam Rasayan signs $300 Mn LOI with Basquevolt for specialty chemicals
Anupam Rasayan India Ltd. signed a non-binding Letter of Intent with BASQUEVOLT, S.A. for the potential supply of specialty chemicals. The agreement spans up to 10 years with an estimated cumulative revenue of $300 million (₹2,500 crore). This move aligns with Anupam Rasayan's strategy to expand in the electronic chemical domain.
Read the summary - Low impact
Anupam Rasayan India Ltd.: Regulation 74(5) Not Applicable for Q1FY27
Anupam Rasayan India Limited confirmed non-applicability of SEBI DP Regulation 74(5) for the quarter ended June 30, 2026. The company's entire shareholding is in dematerialized form, with no rematerialization requests received.
Read the summary - Medium impact
Anupam Rasayan Becomes First Globally to Commercialize ETFA Using Flow Chemistry
Anupam Rasayan India Ltd. has become the first company globally to commercialize ETFA (Ethyl trifluoroacetate) using flow chemistry. The global addressable market for ETFA is estimated at USD 500-600 million. This innovation highlights the company's technological capabilities in complex fluorination chemistry.
Read the summary - Low impact
Anupam Rasayan to Host Investor Meeting on June 9, 2026, at Jhagadia Plant
Anupam Rasayan India Limited will host an investor meeting on June 9, 2026, at its Jhagadia GIDC Plant. The meeting, starting at 10:00 am IST, will be based on publicly available information. The event is hosted by Prabhudas Liladhar Group.
Read the summary - Medium impact
Anupam Rasayan: India Ratings Maintains 'AA-' Rating Watch with Negative Implications
Anupam Rasayan India Limited's Issuer Rating is maintained at 'IND AA-' with Rating Watch Negative Implications by India Ratings. New Non-convertible Debentures worth ₹1,600 million have been assigned 'IND AA-' rating with Rating Watch Negative Implications. Bank loan facilities are rated 'IND AA-' and 'IND A1+' with Rating Watch Negative Implications.
Read the summary - High impact
Anupam Rasayan initiates Open Offer for Bliss GVS Pharma shares
Anupam Rasayan India Limited is making an open offer to acquire 26% of Bliss GVS Pharma Limited for up to ₹829.03 crore at ₹299 per share. This follows a SPA to acquire 43.30% of Bliss GVS Pharma's shares. The announcement details the offer and financial information for both companies.
Read the summary - High impact
Anupam Rasayan Acquires Stake in Bliss GVS Pharma, Expands Pharma Platform
Anupam Rasayan reported highest ever revenue in FY'26 with operating cash flow of ₹334 crore. The company is acquiring 43.3%-48.2% stake in Bliss GVS Pharma to build a pharma platform. Q4 FY'26 consolidated revenue grew 26% YoY to ₹639 crore, and FY'26 revenue increased 65% YoY to ₹2,384 crore. The acquisition of Bliss GVS will be funded by ₹300 crore NCDs and quasi-equity.
Read the summary - Medium impact
Anupam Rasayan India Ltd. Allots ₹160 Crore NCDs to Aditya Birla Capital
Anupam Rasayan India Limited has allotted ₹160 Crore in secured, rated, unlisted NCDs to Aditya Birla Capital Limited. The debentures carry a 10.25% annual coupon rate and mature in 13 months. Proceeds will be used for debt repayment, group company investments, or general corporate purposes.
Read the summary - Low impact
Anupam Rasayan India Ltd.: Audio Recording of Earnings Call for Q4 FY26 Available
Anupam Rasayan India Limited has made the audio recording of its earnings call for the quarter and financial year ended March 31, 2026, available on its website. The call took place on May 25, 2026.
Read the summary - Low impact
Anupam Rasayan Files Newspaper Clippings for Audited Financial Results
Anupam Rasayan India Limited published newspaper clippings for its audited financial results for the quarter and fiscal year ending March 31, 2026. The results were announced following a Board Meeting on May 23, 2026, and published on May 25, 2026.
Read the summary - High impact
Anupam Rasayan Acquires Bliss GVS Pharma, Expands Pharma Portfolio
Anupam Rasayan India Limited announced the acquisition of Bliss GVS Pharma Limited, a pharmaceutical formulations company. The deal involves an open offer for a controlling stake and funding through a ₹300 Crore term loan. This acquisition expands Anupam Rasayan's pharma portfolio and market reach.
Read the summary - High impact
Anupam Rasayan Q4 & FY26 Results: Revenue Grows 65% to ₹23,836 Mn, PAT Up 39% to ₹2,222 Mn
Anupam Rasayan reported FY26 consolidated revenue of ₹23,836 Mn (up 65% YoY) and PAT of ₹2,222 Mn (up 39% YoY). Q4FY26 revenue was ₹6,358 Mn. Key highlights include the acquisition of Jayhawk Fine Chemicals and a definitive agreement to acquire a stake in Bliss GVS Pharma. The company achieved its highest-ever annual sales and operating cash flow.
Read the summary - High impact
Anupam Rasayan to Acquire 43.3-48.2% Stake in Bliss GVS Pharma
Anupam Rasayan India Limited will acquire a 43.3-48.2% stake in Bliss GVS Pharma Limited for ₹300 Crores via term loan and equity instruments. This move aims to strengthen Anupam Rasayan's pharmaceutical value chain presence and global reach.
Read the summary - High impact
Anupam Rasayan to Acquire 43.3-48.2% Stake in Bliss GVS Pharma
Anupam Rasayan India Limited will acquire a 43.3-48.2% equity stake in Bliss GVS Pharma Limited through a definitive agreement. The deal is financed by a ₹300 Crore term loan and other instruments. This acquisition aims to strengthen Anupam Rasayan's pharmaceutical value chain presence and global reach.
Read the summary - High impact
Anupam Rasayan Recommends Final Dividend of ₹1.5/Share, Approves Financials & Acquisition
Anupam Rasayan's Board approved FY26 financial results and recommended a final dividend of ₹1.5 per share. The company will acquire up to 74.20% of Bliss GVS Pharma and raise ₹160 crore via NCDs. Mr. Vishal Thakkar resigned as Deputy CFO.
Read the summary - High impact
Anupam Rasayan Q4FY26 Revenue Up 26% to ₹6,392 Mn, FY26 Revenue Surges 65% to ₹23,836 Mn
Anupam Rasayan reported Q4FY26 revenue of ₹6,392 Mn (up 26% YoY) and FY26 revenue of ₹23,836 Mn (up 65% YoY). FY26 PAT surged 39% to ₹2,222 Mn. The company highlighted the strategic acquisition of Jayhawk Fine Chemicals in the US and a definitive agreement to acquire Bliss GVS Pharma.
Read the summary - Low impact
Anupam Rasayan Re-appoints K.B. Daliya & Associates and Bhanwarlal Gurjar & Co.
Anupam Rasayan India Limited's Board re-appointed M/s. K.B. Daliya & Associates as Internal Auditor and M/s. Bhanwarlal Gurjar & Co. as Cost Auditor. Both appointments are for the financial year 2026-27. The board meeting took place on May 23, 2026.
Read the summary - Low impact
Anupam Rasayan India: Deputy CFO Vishal Thakkar Resigns Effective May 23, 2026
Mr. Vishal Thakkar has resigned as Deputy Chief Financial Officer and Key Managerial Personnel of Anupam Rasayan India Limited, effective May 23, 2026. He cited a desire to explore other opportunities within the Group and his own company. The company confirmed the resignation and will provide transition support.
Read the summary - High impact
Anupam Rasayan to Acquire up to 74.20% of Bliss GVS Pharma for ₹1369.5 Crore
Anupam Rasayan will acquire up to 74.20% of Bliss GVS Pharma for up to ₹1369.51 crore via share purchase and an open offer. The acquisition aims to integrate pharmaceutical value chains. Bliss GVS Pharma reported ₹1000.64 crore turnover as of March 31, 2026. The transaction is expected within 6 months.
Read the summary - High impact
Anupam Rasayan Board Approves FY26 Results, Recommends Dividend, Acquires Bliss GVS Pharma Stake
Anupam Rasayan's Board approved FY26 results and recommended a final dividend of ₹1.5 per share. The company will acquire up to 74.20% of Bliss GVS Pharma and raise ₹160 crore via NCDs. Mr. Vishal Thakkar resigned as Deputy CFO.
Read the summary - Medium impact
Anupam Rasayan Announces Q4 & FY26 Earnings Call on May 25, 2026 at 5:30 PM IST
Anupam Rasayan will hold an earnings call on May 25, 2026, at 5:30 PM IST to discuss the audited financial results for the quarter and financial year ended March 31, 2026. Key participants include Mr. Anand Desai, Mr. Gopal Agrawal, Mr. Amit Khurana, and Mr. Vishal Thakkar. Pre-registration is required via the provided link.
Read the summary - Medium impact
Anupam Rasayan India Ltd. Shareholders Approve Credit Facility Guarantees and Security Interests
Anupam Rasayan India Limited shareholders approved two key resolutions via postal ballot and e-voting on May 7, 2026. The resolutions pertain to guarantees and security interests for a credit facility related to Doriath S.a.r.l. and its subsidiaries. Both resolutions passed with over 99.9% of votes in favour.
Read the summary - Low impact
Anupam Rasayan India Ltd. Confirms Non-Applicability of SEBI Regulation 74(5) for Q4FY26
Anupam Rasayan India Limited confirms non-applicability of SEBI Regulation 74(5) for the quarter ended March 31, 2026. The company's entire shareholding is in dematerialized form, and no rematerialization requests were received.
Read the summary - Low impact
Anupam Rasayan India Ltd. Publishes Newspaper Ads for Postal Ballot and E-Voting
Anupam Rasayan India Limited published newspaper advertisements on April 8, 2026, for its Postal Ballot Notice and Remote E-Voting intimation to members. The ads appeared in Financial Express and Dhabkar. The information will also be available on the company's website.
Read the summary - Medium impact
Anupam Rasayan Announces Postal Ballot for Guarantees and Security Interests
Anupam Rasayan India Limited is seeking shareholder approval via postal ballot for guarantees and security interests related to a credit facility for its subsidiary, Doriath S.à.r.l. The e-voting period is from April 8 to May 7, 2026, with results announced on May 9, 2026.
Read the summary - Medium impact
Anupam Rasayan Board Approves Postal Ballot for Doriath S.à.r.l. Guarantees
Anupam Rasayan India Limited's Board approved a Postal Ballot for shareholders regarding guarantees for Doriath S.à.r.l.'s credit facility. Remote e-voting will occur from April 8 to May 7, 2026. The company also approved security interests over Doriath S.à.r.l. and Jayhawk Fine Chemicals Corporation assets.
Read the summary - Low impact
Anupam Rasayan: Trading Window Closed from April 1 for Financial Results
Anupam Rasayan India Limited will close its trading window from April 1, 2026. The window will reopen 48 hours after the announcement of audited financial results for the quarter and year ended March 31, 2026.
Read the summary - Medium impact
Anupam Rasayan India Limited's Long-Term Rating Reaffirmed at Crisil A+/Stable
Anupam Rasayan India Limited's long-term credit rating has been reaffirmed at Crisil A+/Stable by Crisil Ratings Limited. The short-term rating stands at Crisil A1. Both ratings were removed from 'Rating Watch with Negative Implications'. The total bank loan facilities rated are ₹1369.82 Crore.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio